STOCK TITAN

Ra Medical Systems Announces Expansion to New European Territory

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

FORT MILL, SC / ACCESSWIRE / March 20, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has registered its leading product, VIVO, in Switzerland and has completed first cases in the new territory.

VIVO has already received FDA Clearance and successful registration with a German Competent Authority and MHRA registration allowing VIVO to be sold in the US, twenty-three countries within the European Union and the UK. For manufacturers based outside of Switzerland it is necessary to have a CH REP, or Swiss Authorized Representative, prior to marketing their medical devices in Switzerland.

David Jenkins, CEO and Chairman of the Board, says, "Our strategy in Europe has been to commercialize in areas that accept approvals from our existing competent authorities and to engage distributors where appropriate based physician interest. At the end of 2022, we had interest from physicians in Switzerland to use and purchase VIVO, so we began the process of engaging a Swiss Authorized Representative. We are pleased that we have now completed this process and have begun a successful evaluation with another hospital scheduled to begin later this month."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.



View source version on accesswire.com:
https://www.accesswire.com/744554/Ra-Medical-Systems-Announces-Expansion-to-New-European-Territory

Ra Medical Systems, Inc.

NYSE:RMED

RMED Rankings

RMED Latest News

RMED Stock Data

3.84M
4.60M
36.85%
11%
1.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About RMED

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of